Table 3.
Comparison of our results with previous observational studies of NOACs with 90 days of follow-up
| Dabigatran SITS (n=1240) |
NOACISP (all patients; n=204) |
Gioia et al
19
(n=60) |
SAMURAI (NOACs; n=475) |
RAF-NOAC (dabigatran group; n=381) |
|
| Median/mean* age | 76 (69–82) | 79 (73–84) | 73.5±13.2* | 74.4±9.2* | 73.6±9.9* |
| Median/mean* NIHSS (at admission) |
10 (6–16) | 4 (2–8) | 2 (0–4) at rivaroxaban initiation | 4 (1–13) | 7.7±6.2* |
| Median delay (days) | 8 (4–12) | 5 (3–11) (dabigatran group) | 3 (1.5–6) | 4 (2–7) | 8 (3–14) |
* Mean and SD
NIHSS, National Institutes of Health Stroke Scale; NOACISP, Novel Oral Anticoagulants in Stroke Patients; RAF-NOAC, Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin K Oral Anticoagulants; SITS, Safe Implementation of Treatment in Stroke.